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| INTRODUCTION
Monoclonal plasma proliferative disorders include monoclonal gammopathy of undetermined significance (MGUS), solitary plasmacytoma, multiple myeloma (MM), and AL amyloidosis (AL). 1 In the past, tests for measuring the circulating monoclonal immunoglobulins, such as serum electrophoresis and immunofixation, have been used alongside urine electrophoresis for the identification of such disorders. [1] [2] [3] However, these traditional methods are not sensitive enough to identify nonsecretory MM, many AL patients, and other light chain disorders. 1, [3] [4] [5] In 2001, a new assay based on the use of polyclonal antisera for the detection of serum free light chains (sFLCs) was developed (Freelite; The Binding Site Group Ltd, UK). 6 The Freelite assay can accurately detect and quantify both kappa (κ) and lambda (λ) free light chains (FLC) through polyclonal antibodies recognizing a variety of FLC epitopes. The ratio of κ/λ FLC is a sensitive marker of monoclonality, which is key to the clinical utility of the assay. Because of the greater analytical sensitivity of the Freelite assay for identifying monoclonal sFLC, the International Myeloma Working Group (IMWG) have recommended that sFLC testing is included as part of the screening algorithm for MM and related disorders, alongside serum protein electrophoresis (SPE) and serum immunofixation electrophoresis (IFE). 1, 7 The IMWG recently updated the MM diagnostic criteria to include biomarkers of malignancy (also known as the SLiM criteria), which include an involved/uninvolved Freelite serum FLC ratio greater than or equal to 100 (involved FLC should more than 100 mg/L). 7 This update means that asymptomatic patients, without evidence of related end organ damage (CRAB criteria), can be diagnosed with MM and start therapy if they have one of the SLiM criteria, alongside 10% bone marrow plasma cells or plasmacytoma.
Recently, another sFLC test, based on monoclonal antibodies, became available (N Latex FLC, Siemens, Germany). 8 Only a small number of studies have compared the diagnostic utility of the two assays. [9] [10] [11] This retrospective study is the first such study performed in China, and it aimed to compare the performance of the Freelite and N Latex FLC assays for the diagnosis of monoclonal plasma proliferative disorders.
2 | METHODS
| Patient samples
Consecutive patients who were newly diagnosed with symptomatic monoclonal gammopathies (MGs) including MM, AL amyloidosis, and light chain deposition disease (LCDD) between January 2014 and May 2015 at the First Affiliated Hospital of Zhejiang University (China) were recruited for this study. Repeat samples were not included in the study, and only one sample was permitted per patient.
Only the remnant serum samples after routine testing were analyzed.
Seventy-four remnant serum specimens were stored at −70°C after routine testing, so that the FLC test could be performed retrospectively. At the time of the FLC analysis, the samples were thawed once and thoroughly mixed prior to analysis. This study was approved by The N Latex FLC assay was subjected to a prereaction step for 
| Statistics

The Clinical and Laboratory Standards Institute (CLSI)(EP09-A2-IR) guide to Method Comparison and Bias Estimation using Patient
Samples (EP-09-A2-IR) states that an R 2 ≥ 0.95 is required for establishing that two assays are equivalent. 12 We, therefore, 3 | RESULTS
| Patient characteristics
Samples were from 74 patients, who were recently diagnosed with an MG using commonly accepted criteria. 
| Correlation between the two FLC assays
The recommended reference ranges for the Freelite assay and the N Latex FLC assay were used for the analysis. The concentrations of the κ and λ sFLCs as measured by the two assays are plotted in reference range validated for the N Latex FLC assay, so this patient's monoclonal FLCs would not be identified by the N Latex FLC assay.
| Proportion of patients with measurable FLC
By current IMWG consensus guidelines, one of the criteria for measurable disease in MM is defined as an involved free light chain (iFLC)
greater than 100 mg/L. 3 In this study, we identified more MM patients with measurable disease by the Freelite assay (61.97%) than with the N Latex FLC assay (52.11%). There were five oligosecretory MM patients in this study; all five had measurable disease by Freelite; however, one of these patients did not have measurable disease measured by N Latex FLC. The Freelite assay has shown greater sensitivity than the N latex FLC assay in the detection of monoclonal FLCs in serum. 9 We observed that in samples with extremely high levels of FLC, the difference between the results reported by the two assays was more pro- Of the five NSMM patients included in this study, there were two patients in whom neither assay was able to detect the presence of monoclonal sFLCs, possibly indicating that these patients were true
nonsecretors. However, in the three remaining NSMM patients,
Freelite identified the presence of monoclonal FLCs in all three patients, whereas N Latex FLC was unable to identify the monoclonal such a ratio is yet to be determined for N Latex FLC assay.
The measurable disease criteria are based on studies using the Freelite assays. 3 Our data suggests such criteria may not be applicable Some limitations in the present study should be noted. First, our sample size was relatively small, although our conclusions are in accordance with other studies. Secondly, this is a retrospective study, and the two FLC assays were performed on frozen serum and run on different platforms. These factors may introduce bias into the study, but we believe they should not significantly affect the comparison of the two FLC assays.
Our clinical study demonstrated that although the two assays perform similarly in the detection of FLC, a number of discrepancies were observed. There is a low correlation between the two assays in clinical practice, suggesting the assays are not equivalent. Therefore, the current international guidelines based on the Freelite assays cannot be cross-applied to the N Latex FLC assay. More data are required to establish FLC criteria for N Latex FLC assay.
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